# R1 Clinical-Safety Review — central_neurocytoma

VERDICT: APPROVE

goldens changed: no (intended: n/a)

## 1. SAFETY — pass
No unsafe, misleading, or harmful directive. Every claim is appropriately hedged ("usually",
"reasonable option", "considered", "individualized by the MDT"). Acute obstructive hydrocephalus
is correctly flagged for urgent CSF diversion/neurosurgical referral — the one genuine emergency
for this entity is not buried. No absolute/curative overreach: GTR is called "frequently curative,"
not always. Systemic therapy is correctly stated to have no established role, which prevents the
real harm here (a clinician chasing a non-existent chemo regimen).

## 2. GROUNDING — pass
All content matches standard neuro-oncology / WHO CNS classification standard of care:
- Central neurocytoma = intraventricular neuronal tumor, WHO CNS grade 2, septum pellucidum /
  foramen of Monro, young-to-middle-aged adults — correct.
- Maximal safe resection as primary/definitive therapy, extent of resection as dominant outcome
  driver — correct.
- Adjuvant RT / SRS reserved for incomplete resection, atypical histology (elevated Ki-67/MIB-1),
  or recurrence — correct and standard.
- Synaptophysin for neuronal differentiation, Ki-67/MIB-1 for atypical stratification, IDH/1p19q/
  ATRX to separate from oligodendroglioma — correct.
No fabricated regimen, trial, drug name, or statistic. Adversarial .verdict.md (VERDICT: CLEAN)
confirms zero fabricated regimens/statistics.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, Gy, fractionation, or numbered dosing schedule. The only numerals are "WHO CNS
grade 2", the 1-4 sequence list (therapy ordering, not a schedule), and "12th ed." in the citation.
Confirmed independently and consistent with the .verdict.md dose grep.

## 4. SCOPE — pass
Framed as decision-support, not directive: MDT/neurosurgery/radiation-oncology referral is
repeatedly deferred to; surgical approach "chosen by the neurosurgical team"; surveillance
"individualized." Stays within reference-KB management scope.

## 5. ADVERSARIAL FLAGS — resolved
The prior R1-blocking issue was a DeVita mis-attribution (whole narrative credited to DeVita despite
DeVita having no dedicated management passage). The .verdict.md confirms this is FIXED: the intro
flag and Sources line now explicitly relabel the content as "general neuro-oncology standard of care
and WHO CNS tumor classification principles ... not from DeVita's section on this disease," and state
no clinical claim is attributed to DeVita. No claim is mis-sourced to DeVita in the body. This meets
the "relabelled as general-standard, not DeVita-specific" bar, so the previously-flagged issue is not
still present. APPROVE is warranted.

## Note (advisory, non-blocking)
The sidecar's own flag says content is "also reflected in the existing reference JSON in this KB."
That cross-reference was not independently re-diffed here; recommend the merge step confirm the JSON
overview/histology fields do not contradict this narrative. This is a consistency check, not a
fabrication or safety concern.
